Where Pay-For-Delay Stands 2 Years After Actavis
The second year of litigation after the U.S. Supreme Court cleared the way for challenges to so-called pay-for-delay patent settlements by drugmakers has brought a host of firsts for the burgeoning...To view the full article, register now.
Already a subscriber? Click here to view full article